Luly Jay R.'s Form 4 filing
Enanta Pharmaceuticals Inc (ENTA) · filed Mar 14, 2023
- Accession no.
- 0001062993-23-006867
- Filed
- Mar 14, 2023
- Trade date
- Mar 13, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.26M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Luly Jay R.CIK 0001571211 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2023 | Common Stock | MOption exerciseAcquired | +27,912 | $14.00 | +$390,768 | 847,722 | Direct | |
| Mar 13, 2023 | Common Stock | SSaleDisposed | −10,697 | $44.81 | −$479,332.57 | 837,025 | Direct | |
| Mar 13, 2023 | Common Stock | SSaleDisposed | −15,649 | $45.31 | −$709,056.19 | 821,376 | Direct | |
| Mar 13, 2023 | Common Stock | SSaleDisposed | −1,566 | $46.13 | −$72,239.58 | 819,810 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2023 | Common Stock | MOption exerciseDisposed | −27,912 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.